Evaluating the accessibility and capacity of SARS-CoV-2 vaccination and analyzing convenience-related factors during the Omicron variant epidemic in Beijing, China

Author:

Duan Yuping123ORCID,Jiang Mingyue123,Suo Luodan4,Xu Mingyu4,Li Xiaomei4,Wang Qing5,Bai Chengxu4,Wu Jiang4,Xu Zheng6,Yang Weizhong123,Feng Luzhao123ORCID,Li Juan47ORCID

Affiliation:

1. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2. State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China

3. Key Laboratory of Pathogen Infection Prevention and Control, Ministry of Education, Peking Union Medical College, Beijing, China

4. Beijing Centre for Disease Prevention and Control, Beijing Research Centre for Preventive Medicine, Beijing, China

5. Xicheng District Centre for Diseases Control and Prevention, Beijing, China

6. Beijing Municipal Health Commission, Beijing, China

7. Capital Medical University, Beijing, China

Funder

Natural Science Foundation of Beijing Municipality

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference28 articles.

1. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5

2. China CPsGotPsRo. The latest situation of coronavirus disease 2019 (COVID-19) as of 24: 00 on December 23. Health Commission of The People’s Republic Of China; 2022. https://www.gov.cn/xinwen/2022-12/24/content_5733356.htm.

3. The low proportion of severe cases in this round of COVID-19 is mainly manifested by the aggravation of underlying diseases. 2022. https://news.cctv.com/2022/12/06/ARTIwRq3t7CKO3p3Z129QqD6221206.shtml.

4. Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China

5. China CPsGotPsRo. Continue to improve the scientific precision level of prevention and control – interpretation of the “new Ten points” in the press conference of the joint prevention and control mechanism of the state council. The Xinhua News Agency; 2022. http://www.gov.cn/zhengce/2022-12/08/content_5730631.htm.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3